Schizophrenia News and Research

Latest Schizophrenia News and Research

Study highlights urgent need for improved care for schizophrenia

New research finds that adults with schizophrenia spectrum disorders have high rates of comorbid mental and substance use disorders and significant social and economic disadvantages, and only 26% received minimally adequate treatment.

23 Sep 2024

Fighting staff shortages with scholarships, California bill aims to boost mental health courts

A seemingly innocuous proposal to offer scholarships for mental health workers in California's new court-ordered treatment program has sparked debate over whether the state should prioritize that program or tackle a wider labor shortage in behavioral health services.

20 Sep 2024

Understanding the risk of NMS in young patients

A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years.

19 Sep 2024

Genetic analysis challenges the idea that loneliness directly causes diseases

Research reveals that loneliness is linked to numerous diseases observationally, but genetic analysis shows it's likely a marker rather than a cause.

18 Sep 2024

Loneliness may not be a direct cause of disease

A study reveals loneliness correlates with 13 illness categories, highlighting its role as a potential proxy marker rather than a direct risk factor.

17 Sep 2024

New consortium tackles genetic origins of neurodevelopmental and psychiatric disorders

Neurodevelopmental and psychiatric disorders (NPD) including schizophrenia, bipolar disorder, autism, and depression are detrimental to individuals, their families and society as a whole, and in many cases still lack effective treatments.

12 Sep 2024

High-dose amphetamine use linked to increased risk of psychosis or mania

Prescribing rates for stimulants that treat attention-deficit/hyperactivity disorder (ADHD) have increased significantly over the past decade, with some of the largest increases reported during the COVID-19 pandemic.

12 Sep 2024

TAAR1 gene: A new key to mental health

In the complex landscape of mental health research, a new peer-reviewed Viewpoint review sheds light on an underexplored genetic player: the trace amine-associated receptor 1 (TAAR1). Published in Genomic Psychiatry (ISSN: 2997-2388, Genomic Press, New York), this thought-provoking analysis suggests that mutations in the TAAR1 gene may be a crucial piece of the puzzle in understanding and treating neuropsychiatric disorders.

11 Sep 2024

New insights into the genetics of schizophrenia

In the complex landscape of mental health research, a new peer-reviewed viewpoint offers a critical examination of how genes and environment conspire to influence schizophrenia risk. Published in Genomic Psychiatry (ISSN: 2997-2388, Genomic Press, New York), this thought-provoking analysis by researchers Natassia Robinson and Sarah E. Bergen from Karolinska Institutet in Stockholm, Sweden, brings together cutting-edge findings from genetics and epidemiology.

11 Sep 2024

COVID-19 lockdowns accelerated brain aging in adolescent girls, researchers find

Researchers discovered that COVID-19 lockdowns accelerated cortical thinning in adolescent brains, with females experiencing more significant and widespread changes than males, indicating a higher developmental impact on female brains.

10 Sep 2024

Rethinking cognitive deficits and schizophrenia risk through genetic insights

In a comprehensive review of recent genetic and population studies, published in the peer-reviewed medical journal Genomic Psychiatry (Genomic Press, New York), Professors Michael Owen and Michael O'Donovan of Cardiff University's Centre for Neuropsychiatric Genetics and Genomics present evidence that challenges conventional wisdom about cognitive deficits in schizophrenia

6 Sep 2024

Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders

Misha Kudryshev's lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia.

4 Sep 2024

Semaglutide does not increase risk of depression or suicidal thoughts

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine.

4 Sep 2024